


**Amendments to the Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-21 (canceled)

22. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (I):



(I)

wherein: X is -CHR<sub>3</sub>-, -CHR<sub>3</sub>-alkyl-, or -CHR<sub>3</sub>-alkenyl-;

Z is -S-, -SO-, or -SO<sub>2</sub>-;

R<sub>1</sub> is selected from the group consisting of:

- alkyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkenyl;
- R<sub>4</sub>-aryl;
- R<sub>4</sub>-heteroaryl;
- R<sub>4</sub>-heterocyclyl;

R<sub>2</sub> is selected from the group consisting of:

-hydrogen;  
-alkyl;  
-alkenyl;  
-aryl;  
-heteroaryl;  
-heterocyclyl;  
-alkyl-Y-alkyl;  
-alkyl-Y-alkenyl;  
-alkyl-Y-aryl; and  
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;  
-halogen;  
-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-N(R<sub>3</sub>)<sub>2</sub>;  
-CO-C<sub>1-10</sub> alkyl;  
-CO-O-C<sub>1-10</sub> alkyl;  
-N<sub>3</sub>;  
-aryl;  
-heteroaryl;  
-heterocyclyl;  
-CO-aryl; and  
-CO-heteroaryl;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;

R<sub>4</sub> is alkyl or alkenyl;

Y is -O- or -S(O)<sub>0-2</sub>;

n is 0 to 4; and

each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl,

C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.


23-25 (canceled)

26. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the group consisting of:

2-butyl-1-[4-(phenylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[4-(phenylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[2-(phenylthio)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(phenylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(phenylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-methyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-ethyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-hexyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[5-(methylthio)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[5-(methylsulfinyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
2-butyl-1-[3-(methylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and  
2-butyl-1-[3-(phenylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;  
or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

27-30 (canceled)

31. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (II):



(II)

wherein: X is  $-\text{CHR}_3-$ ,  $-\text{CHR}_3\text{-alkyl-}$ , or  $-\text{CHR}_3\text{-alkenyl-}$ ;

Z is  $-\text{S-}$ ,  $-\text{SO-}$ , or  $-\text{SO}_2-$ ;

$\text{R}_1$  is selected from the group consisting of:

- alkyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkenyl;
- $-\text{R}_4\text{-aryl}$ ;
- $-\text{R}_4\text{-heteroaryl}$ ; and
- $-\text{R}_4\text{-heterocyclyl}$ ;

$\text{R}_2$  is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkyl-Y-alkyl;
- alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-N(R<sub>3</sub>)<sub>2</sub>;

-CO-N(R<sub>3</sub>)<sub>2</sub>;

-CO-C<sub>1-10</sub> alkyl;

-CO-O-C<sub>1-10</sub> alkyl;

-N<sub>3</sub>;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R<sub>3</sub> is independently H or C<sub>1-10</sub> alkyl;

R<sub>4</sub> is alkyl or alkenyl;

Y is -O- or -S(O)<sub>0-2</sub>;

n is 0 to 4; and

each R present is independently selected from the group consisting of C<sub>1-10</sub> alkyl,

C<sub>1-10</sub> alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

32. (previously presented) The compound 2-butyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine or a pharmaceutically acceptable salt thereof.

33-34 (canceled)

35. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of claim 32 that induces cytokine biosynthesis.